Translocation of high-mobility group box-1 protein is induced by diabetes and high glucose in retinal pericytes

Molecular Medicine Reports

Volumn 14, Issue 4, 2016, Pages 3655-3661

  Kim, Junghyun ^a   Kim, Chan Sik ^a   Sohn, Eunjin ^a   Kim, Jin Sook ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Diabetic retinopathy; High mobility group box 1; Retinal pericyte

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; AGER PROTEIN, RAT; HBP1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DIABETES MELLITUS; DIABETIC RETINOPATHY; IMMUNOFLUORESCENCE TEST; INTRACELLULAR TRANSPORT; MALE; NONHUMAN; PERICYTE; PROMOTER REGION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RAT; RETINA BLOOD VESSEL; RETINA CELL; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSCRIPTION INITIATION; ANIMAL; CELL CULTURE; METABOLISM; PATHOLOGY; RETINA; SPRAGUE DAWLEY RAT;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; CELLS, CULTURED; DIABETIC RETINOPATHY; GLUCOSE; HMGB1 PROTEIN; MALE; NF-KAPPA B; PERICYTES; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; RETINA;

EID: 84988474740     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5702     Document Type: Article

References (49)

1. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
2. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, et al: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18: 1450-1452, 2004.
3. King GL: The role of inflammatory cytokines in diabetes and its complications. J Periodontol 79: 1527-1534, 2008.
4. Muller S, Ronfani L and Bianchi ME: Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255: 332-343, 2004.
5. Bianchi ME: Significant (re)location: How to use chromatin and/or abundant proteins as messages of life and death. Trends Cell Biol 14: 287-293, 2004.
6. Ulloa L and Messmer D: High-mobility group box 1 (HMGB1) protein: Friend and foe. Cytokine Growth Factor Rev 17: 189-201, 2006.
7. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
8. Bianchi ME and Manfredi A: Chromatin and cell death. Biochim Biophys Acta 1677: 181-186, 2004.
9. Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331-342, 2005.
10. Jiang W, Li J, Gallowitsch-Puerta M, Tracey KJ and Pisetsky DS: The effects of CpG DNA on HMGB1 release by murine macrophage cell lines. J Leukoc Biol 78: 930-936, 2005.
11. Riedemann NC, Guo RF and Ward PA: The enigma of sepsis. J Clin Invest 112: 460-467, 2003.
12. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH and Suffredini AF: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 2652-2660, 2003.
13. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999.
14. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, et al: High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48: 971-981, 2003.
15. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M and Maruyama I: HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 16: 136-143, 2007.
16. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, Ilyinskaya O, Tararak E and Bobik A: Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: Role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 24: 2320-2325, 2004.
17. Yao D and Brownlee M: Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59: 249-255, 2010.
18. Lupo G, Motta C, Giurdanella G, Anfuso CD, Alberghina M, Drago F, Salomone S and Bucolo C: Role of phospholipases A2 in diabetic retinopathy: In vitro and in vivo studies. Biochem Pharmacol 86: 1603-1613, 2013.
19. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N: Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46: 1440-1444, 2005.
20. Jonas JB and Söfker A: Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132: 425-427, 2001.
21. Cai J, Kehoe O, Smith GM, Hykin P and Boulton ME: The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci 49: 2163-2171, 2008.
22. Capetandes A and Gerritsen ME: Simplified methods for consistent and selective culture of bovine retinal endothelial cells and pericytes. Invest Ophthalmol Vis Sci 31: 1738-1744, 1990.
23. Kondo T, Hosoya K, Hori S, Tomi M, Ohtsuki S, Takanaga H, Nakashima E, Iizasa H, Asashima T, Ueda M, et al: Establishment of conditionally immortalized rat retinal pericyte cell lines (TR-rPCT) and their application in a co-culture system using retinal capillary endothelial cell line (TR-iBRB2). Cell Struct Funct 28: 145-153, 2003.
24. Wang YL, Hui YN, Guo B and Ma JX: Strengthening tight junctions of retinal microvascular endothelial cells by pericytes under normoxia and hypoxia involving angiopoietin-1 signal way. Eye (Lond) 21: 1501-1510, 2007.
25. Cacicedo JM, Benjachareowong S, Chou E, Ruderman NB and Ido Y: Palmitate-induced apoptosis in cultured bovine retinal pericytes: Roles of NAD (P)H oxidase, oxidant stress, and ceramide. Diabetes 54: 1838-1845, 2005.
26. Schreiber E, Matthias P, Müller MM and Schaffner W: Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17: 6419, 1989.
27. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
28. von Knethen A, Callsen D and Brüne B: NF-kappaB and AP-1 activation by nitric oxide attenuated apoptotic cell death in RAW 264. 7 macrophages. Mol Biol Cell 10: 361-372, 1999.
29. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ and Clark GJ: RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 278: 28045-28051, 2003.
30. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, et al: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761, 1995.
31. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K and Schmidt AM: Receptor for AGE (RAGE): Weaving tangled webs within the inflammatory response. Curr Mol Med 7: 743-751, 2007.
32. Motiejunaite R and Kazlauskas A: Pericytes and ocular diseases. Exp Eye Res 86: 171-177, 2008.
33. Kuwabara T and Cogan DG: Retinal vascular patterns. VII. Acellular change. Invest Ophthalmol 4: 1049-1064, 1965.
34. Sims DE: Diversity within pericytes. Clin Exp Pharmacol Physiol 27: 842-846, 2000.
35. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE and Adamis AP: Leukocyte-mediated endothelial cell i njury and death in the diabetic retina. Am J Pathol 158: 147-152, 2001.
36. Kern TS: Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007: 95103, 2007.
37. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, et al: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901, 1999.
38. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, et al: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50: 2792-2808, 2001.
39. Thornalley PJ: Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE)-an introduction. Mol Nutr Food Res 51: 1107-1110, 2007.
40. Ramasamy R, Yan SF and Schmidt AM: Arguing for the motion: Yes, RAGE is a receptor for advanced glycation endproducts. Mol Nutr Food Res 51: 1111-1115, 2007.
41. Heizmann CW: The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: Arguing against the motion. Mol Nutr Food Res 51: 1116-1119, 2007.
42. Foell D, Wittkowski H, Vogl T and Roth J: S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. J Leukoc Biol 81: 28-37, 2007.
43. Yamagishi S, Takeuchi M, Matsui T, Nakamura K, Imaizumi T and Inoue H: Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 579: 4265-4270, 2005.
44. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D and Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897, 1994.
45. Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663, 2000.
46. Kim J, Kim OS, Kim CS, Kim NH and Kim JS: Cytotoxic role of methylglyoxal in rat retinal pericytes: Involvement of a nuclear factor-kappaB and inducible nitric oxide synthase pathway. Chem Biol Interact 188: 86-93, 2010.
47. Kim J, Son JW, Lee JA, Oh YS and Shinn SH: Methylglyoxal induces apoptosis mediated by reactive oxygen species in bovine retinal pericytes. J Korean Med Sci 19: 95-100, 2004.
48. Romeo G, Liu WH, Asnaghi V, Kern TS and Lorenzi M: Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51: 2241-2248, 2002.
49. Zhang SX, Wang JJ, Dashti A, Wilson K, Zou MH, Szweda L, Ma JX and Lyons TJ: Pigment epithelium-derived factor mitigates inflammation and oxidative stress in retinal pericytes exposed to oxidized low-density lipoprotein. J Mol Endocrinol 41: 135-143, 2008.